MalayalamNewsableKannadaKannadaPrabhaTeluguTamilBanglaHindiMarathiMyNation
Add Preferred SourceGoogle-icon
  • Facebook
  • Twitter
  • whatsapp
  • YT video
  • insta
  • Latest News
  • India
  • World
  • Business
  • Markets
  • Sports
  • Entertainment
  • Technology
  • Auto
  • Lifestyle
  • Home
  • India
  • Top Stories
  • 'Made in India' Covid vaccine gets nod for human clinical trial

'Made in India' Covid vaccine gets nod for human clinical trial

India's first indigenous mRNA vaccine candidate has received approval from the Drugs Controller General of India to initiate Phase I/II human clinical trial. 

2 Min read
Asianet Newsable English
Published : Dec 11 2020, 07:45 PM IST
Share this Photo Gallery
  • FB
  • TW
  • Linkdin
  • Whatsapp
  • GNFollow Us
13
<p>The novel mRNA vaccine candidate, HGCO19 has been developed by Gennova, Pune and supported with seed grant under the Ind CEPI mission of Department of Biotechnology of Science &amp; Technology ministry.<br />&nbsp;</p><p>HGCO19 has already demonstrated safety, immunogenicity, neutralization antibody activity in animals.&nbsp;<br />&nbsp;</p><p>The neutralizing antibody response of the vaccine in mice and non human primates was comparable with the sera from the convalescent patients of COVID 19.<br />&nbsp;</p><p>Two other vaccines Covishield and Covaxin are in the third stage of clinical trials and have parallely applied for emergency use authorisation to the DCGI.&nbsp;</p>

<p>The novel mRNA vaccine candidate, HGCO19 has been developed by Gennova, Pune and supported with seed grant under the Ind-CEPI mission of Department of Biotechnology of Science &amp; Technology ministry.<br />&nbsp;</p><p>HGCO19 has already demonstrated safety, immunogenicity, neutralization antibody activity in animals.&nbsp;<br />&nbsp;</p><p>The neutralizing antibody response of the vaccine in mice and non-human primates was comparable with the sera from the convalescent patients of COVID-19.<br />&nbsp;</p><p>Two other vaccines -- Covishield and Covaxin -- are in the third stage of clinical trials and have parallely applied for emergency use authorisation to the DCGI.&nbsp;</p>

The novel mRNA vaccine candidate, HGCO19 has been developed by Gennova, Pune and supported with seed grant under the Ind-CEPI mission of Department of Biotechnology of Science & Technology ministry.
 

HGCO19 has already demonstrated safety, immunogenicity, neutralization antibody activity in animals. 
 

The neutralizing antibody response of the vaccine in mice and non-human primates was comparable with the sera from the convalescent patients of COVID-19.
 

Two other vaccines -- Covishield and Covaxin -- are in the third stage of clinical trials and have parallely applied for emergency use authorisation to the DCGI. 

Add Asianet Newsable as a Preferred SourcegooglePreferred
23
<p><strong>What are mRNA vaccines?</strong></p><p>The mRNA vaccines do not use the conventional model to produce immune response.&nbsp; Instead, mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus.<br />&nbsp;</p><p>The host body uses this to produce the viral protein that is recognized and thereby making the body mount an immune response against the disease.<br />&nbsp;</p><p>mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline.&nbsp;</p>

<p><strong>What are mRNA vaccines?</strong></p><p>The mRNA vaccines do not use the conventional model to produce immune response.&nbsp; Instead, mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus.<br />&nbsp;</p><p>The host body uses this to produce the viral protein that is recognized and thereby making the body mount an immune response against the disease.<br />&nbsp;</p><p>mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline.&nbsp;</p>

What are mRNA vaccines?

The mRNA vaccines do not use the conventional model to produce immune response.  Instead, mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus.
 

The host body uses this to produce the viral protein that is recognized and thereby making the body mount an immune response against the disease.
 

mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline. 

33
<p><strong>mRNA vaccines are considered safe</strong></p><p>The mRNA vaccine is considered safe as is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. They are expected to be highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm.&nbsp;<br />&nbsp;</p><p>Additionally, mRNA vaccines are fully synthetic and do not require a host for growth, e.g., eggs or bacteria.&nbsp;<br />&nbsp;</p><p>Therefore, they can be quickly manufactured in an inexpensive manner under cGMP conditions to ensure their "availability" and "accessibility" for mass vaccination on a sustainable basis.</p>

<p><strong>mRNA vaccines are considered safe</strong></p><p>The mRNA vaccine is considered safe as is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. They are expected to be highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm.&nbsp;<br />&nbsp;</p><p>Additionally, mRNA vaccines are fully synthetic and do not require a host for growth, e.g., eggs or bacteria.&nbsp;<br />&nbsp;</p><p>Therefore, they can be quickly manufactured in an inexpensive manner under cGMP conditions to ensure their "availability" and "accessibility" for mass vaccination on a sustainable basis.</p>

mRNA vaccines are considered safe

The mRNA vaccine is considered safe as is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. They are expected to be highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm. 
 

Additionally, mRNA vaccines are fully synthetic and do not require a host for growth, e.g., eggs or bacteria. 
 

Therefore, they can be quickly manufactured in an inexpensive manner under cGMP conditions to ensure their "availability" and "accessibility" for mass vaccination on a sustainable basis.

About the Author

AN
Asianet Newsable English
Latest Videos
Recommended Stories
Recommended image1
Mumbai woman and lover slit husband's throat, ride body on scooty, dump it; Arrested
Recommended image2
Winter grips Jammu and Kashmir: Freezing temperatures, snowfall hit Srinagar; Winter festivities draw tourists
Recommended image3
Delhi court denies bail to alleged drug syndicate kingpin Waseem Shaikh
Recommended image4
SC seeks Centre, ECI reply on plea for lifetime ban on convicted politicians
Recommended image5
J&K: Security forces recover AK rifles, ammo in Kupwara anti-terror operation
News
Breaking News TodayLatest News TodayIndia NewsWorld NewsKarnataka NewsKerala NewsIndian Defence NewsBengaluru News
Entertainment
Entertainment NewsOTT ReleaseBigg BossMovie ReviewsBox Office Collection
Sports
Sports NewsCricket NewsFootball NewsWWE NewsOther Sports
Lifestyle
Lifestyle NewsFood and RecipesHealth NewsAstrologyCareer NewsWeb Stories
Business
Business newsShare Market NewsGold PriceDA Hike8th Pay CommissionTechnology NewsAutomobile News
Weather
WeatherKolkata WeatherChennai WeatherBengaluru Weather
Asianet
Follow us on
  • Facebook
  • Twitter
  • whatsapp
  • YT video
  • insta
  • Download on Android
  • Download on IOS
  • About Website
  • Terms of Use
  • Privacy Policy
  • CSAM Policy
  • Complaint Redressal - Website
  • Compliance Report Digital
  • Investors
© Copyright 2025 Asianxt Digital Technologies Private Limited (Formerly known as Asianet News Media & Entertainment Private Limited) | All Rights Reserved